Jan van de Winkel

New Capabilities

Leading Genmab's epcoritamab collaboration with AbbVie

AbbVie and Genmab reported on October 5 that adding epcoritamab to the R-CHOP chemotherapy combination cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. It is the first phase 3 trial of a bispecific antibody, a drug that steers the body's T cells onto cancer cells, to beat the 20-year-old R-CHOP backbone.

Updated Oct 24